As development of low volume, high-cost rare and orphan drugs dominate the specialty drug pipeline, payers are increasingly restricting or managing access to these transformative therapies.

RE understands the unique challenges and market access dynamics required to bring rare and orphan therapies to market. RE works with clients to deliver insights and actionable recommendations to ensure a patient-focused market access and supply chain strategy

• Craft an effective pricing strategy
• Define, negotiate, and monitor innovative contracts

• Define the patient, provider, and payer value
• Assess the kind and level of patient support services that make all the difference